

III. References

The following references marked with an asterisk (*) are on display at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they also are available electronically at <https://www.regulations.gov>. References without asterisks are not on public display at <https://www.regulations.gov> because they have copyright restriction. Some may be available at the website address, if listed. References without asterisks are available for viewing only at the Dockets Management Staff. FDA has verified the website addresses, as of the date this document publishes in the **Federal Register**, but websites are subject to change over time.

1. Beaver J.A., L.J. Howie, L. Pelosof, et al., "A 25-Year Experience of U.S. Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review." *JAMA Oncology*. 2018; 4(6):849-856.
2. Sullivan H.W., A.C. O'Donoghue, K.T. David, et al., "Disclosing Accelerated Approval on Direct-to-Consumer Prescription Drug websites." *Pharmacoepidemiology and Drug Safety*. 2018;27:1277-1280. <https://doi.org/10.1002/pds.4664>.
3. Cutrona, S.L., K.M. Mazor, S.N. Vieux, et al., "Health Information-Seeking on Behalf of Others: Characteristics of 'Surrogate Seekers'." *Journal of Cancer Education*. 2015;30:12-19. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282983/>.
4. Sadasivam, R.S., R.L. Kinney, S.C. Lemon, et al., "Internet Health Information Seeking Is a Team Sport: Analysis of the Pew Internet Survey." *International Journal of Medical Informatics*. 2013;82:193-200.
- * 5. Bangerter, L.R., J. Griffin, K. Harden, et al., "Health Information-Seeking Behaviors of Family Caregivers: Analysis of the Health Information National Trends Survey." *JMIR Aging*. 2019;2:e11237. <https://aging.jmir.org/2019/1/e11237/>.
6. von Itzstein, M.S., E. Railey, M.L. Smith, et al., "Patient Familiarity with, Understanding of, and Preferences for Clinical Trial Endpoints and Terminology." *Cancer*. 2021;126:1605-1613.
7. Kelly, B.J., D.J. Rupert, K.J. Aikin, et al., "Development and Validation of Prescription Drug Risk, Efficacy, and Benefit Perception Measures in the Context of Direct-to-Consumer Prescription Drug Advertising." *Research in Social and Administrative Pharmacy*. 2021;17:942-955.

Dated: March 17, 2022.

Andi Lipstein Fristedt,
Deputy Commissioner for Policy, Legislation, and International Affairs, U.S. Food and Drug Administration.

[FR Doc. 2022-06220 Filed 3-23-22; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

National Vaccine Injury Compensation Program; List of Petitions Received

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: HRSA is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by Section 2112(b)(2) of the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

FOR FURTHER INFORMATION CONTACT: For information about requirements for filing petitions, and the Program in general, contact Lisa L. Reyes, Clerk of Court, United States Court of Federal Claims, 717 Madison Place NW, Washington, DC 20005, (202) 357-6400. For information on HRSA's role in the Program, contact the Director, National Vaccine Injury Compensation Program, 5600 Fishers Lane, Room 08N146B, Rockville, Maryland 20857; (301) 443-6593, or visit our website at: <http://www.hrsa.gov/vaccinecompensation/index.html>.

SUPPLEMENTARY INFORMATION: The Program provides a system of no-fault compensation for certain individuals who have been injured by specified childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C. 300aa-10 *et seq.*, provides that those seeking compensation are to file a petition with the United States Court of Federal Claims and to serve a copy of the petition to the Secretary of HHS, who is named as the respondent in each proceeding. The Secretary has delegated this responsibility under the Program to HRSA. The Court is directed by statute to appoint special masters who take evidence, conduct hearings as

appropriate, and make initial decisions as to eligibility for, and amount of, compensation.

A petition may be filed with respect to injuries, disabilities, illnesses, conditions, and deaths resulting from vaccines described in the Vaccine Injury Table (the Table) set forth at 42 CFR 100.3. This Table lists for each covered childhood vaccine the conditions that may lead to compensation and, for each condition, the time period for occurrence of the first symptom or manifestation of onset or of significant aggravation after vaccine administration. Compensation may also be awarded for conditions not listed in the Table and for conditions that are manifested outside the time periods specified in the Table, but only if the petitioner shows that the condition was caused by one of the listed vaccines.

Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa-12(b)(2), requires that "[w]ithin 30 days after the Secretary receives service of any petition filed under section 2111 the Secretary shall publish notice of such petition in the **Federal Register**." Set forth below is a list of petitions received by HRSA on February 1, 2022, through February 28, 2022. This list provides the name of petitioner, city and state of vaccination (if unknown then city and state of person or attorney filing claim), and case number. In cases where the Court has redacted the name of a petitioner and/or the case number, the list reflects such redaction.

Section 2112(b)(2) also provides that the special master "shall afford all interested persons an opportunity to submit relevant, written information" relating to the following:

1. The existence of evidence "that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition," and

2. Any allegation in a petition that the petitioner either:

a. "[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Vaccine Injury Table but which was caused by" one of the vaccines referred to in the Table, or

b. "[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine" referred to in the Table.

In accordance with Section 2112(b)(2), all interested persons may submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the United States Court of Federal Claims at the address listed above (under the heading **FOR FURTHER INFORMATION CONTACT**), with a copy to HRSA addressed to Director, Division of Injury Compensation Programs, Health Systems Bureau, 5600 Fishers Lane, 08N146B, Rockville, Maryland 20857. The Court's caption (*Petitioner's Name v. Secretary of HHS*) and the docket number assigned to the petition should be used as the caption for the written submission. Chapter 35 of title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the Program.

Carole Johnson,
Administrator.

List of Petitions Filed

1. Michelle Davis on behalf of A.D., Phoenix, Arizona, Court of Federal Claims No: 22-0098V
2. Barbara Sciortino, Las Vegas, Nevada, Court of Federal Claims No: 22-0099V
3. Ruby Sharma Dhital, West Hartford, Connecticut, Court of Federal Claims No: 22-0101V
4. Chelsea Smith on behalf of C.S., Danville, Kentucky, Court of Federal Claims No: 22-0103V
5. Brechen Santeramo, Fort Collins, Colorado, Court of Federal Claims No: 22-0104V
6. Shawn Geiger, Hackettstown, New Jersey, Court of Federal Claims No: 22-0106V
7. Roberta Johnson, Winfield, Illinois, Court of Federal Claims No: 22-0107V
8. Samuel Martin, Oklahoma City, Oklahoma, Court of Federal Claims No: 22-0109V
9. Marijane Angels, Southington, Connecticut, Court of Federal Claims No: 22-0112V
10. Suzanne Kallin, Los Angeles, California, Court of Federal Claims No: 22-0113V
11. Maria Sims, Philadelphia, Pennsylvania, Court of Federal Claims No: 22-0115V
12. Karen Miller, Seattle, Washington, Court of Federal Claims No: 22-0116V
13. Jerry Brown, Greenville, Texas, Court of Federal Claims No: 22-0118V
14. Demetrius Lockett, Detroit, Michigan, Court of Federal Claims No: 22-0119V
15. Pamela Allen, Fairburn, Georgia, Court of Federal Claims No: 22-0122V
16. Ann Marie Indorf on behalf of K.I., Phoenix, Arizona, Court of Federal Claims No: 22-0123V
17. Dana Mowery, Delaware, Ohio, Court of Federal Claims No: 22-0124V
18. Ronald L. Jopes, Elizabethtown, Kentucky, Court of Federal Claims No: 22-0125V
19. Anne Rosenthal, Palo Alto, California, Court of Federal Claims No: 22-0126V
20. Joan Steede, Rockford, Illinois, Court of Federal Claims No: 22-0128V
21. Andrew Short, St. Paul, Minnesota, Court of Federal Claims No: 22-0129V
22. Herbert St. Amant, Cypress, California, Court of Federal Claims No: 22-0130V
23. Norman Michaud, Auburn, Maine, Court of Federal Claims No: 22-0134V
24. Jordanna Ross, La Porte, Indiana, Court of Federal Claims No: 22-0136V
25. Gary Krugel, Antigo, Wisconsin, Court of Federal Claims No: 22-0139V
26. CarolAnn Sinclair, Anacortes, Washington, Court of Federal Claims No: 22-0140V
27. Sheetal Paliwal, Libertyville, Illinois, Court of Federal Claims No: 22-0141V
28. Jonessa Casarez on behalf of A.C., Phoenix, Arizona, Court of Federal Claims No: 22-0142V
29. Hunter Miller, Phoenix, Arizona, Court of Federal Claims No: 22-0143V
30. Kelly Quinn, Tempe, Arizona, Court of Federal Claims No: 22-0144V
31. Mary Walsh, Valatie, New York, Court of Federal Claims No: 22-0148V
32. Arnold Saitow, Boston, Massachusetts, Court of Federal Claims No: 22-0150V
33. Zachary Hemenway, Staples, Minnesota, Court of Federal Claims No: 22-0153V
34. John Owen, West Des Moines, Iowa, Court of Federal Claims No: 22-0155V
35. Jordan Aguilar, Phoenix, Arizona, Court of Federal Claims No: 22-0156V
36. Jean Deoleo and Dayre Deoleo on behalf of I.D., Miami, Florida, Court of Federal Claims No: 22-0157V
37. Nanoya Burgan, Lawrenceville, Georgia, Court of Federal Claims No: 22-0158V
38. Mary White on behalf of M.A., Phoenix, Arizona, Court of Federal Claims No: 22-0159V
39. Muriel J. Duval, Las Vegas, Nevada, Court of Federal Claims No: 22-0160V
40. Florence Barrett, Tacoma, Washington, Court of Federal Claims No: 22-0161V
41. Ljubitzka Ghiardi, Phoenix, Arizona, Court of Federal Claims No: 22-0162V
42. Clara Nickels, Phoenix, Arizona, Court of Federal Claims No: 22-0167V
43. Denise Warburton on behalf of C.C., Phoenix, Arizona, Court of Federal Claims No: 22-0169V
44. Sandra Fox, Pittsburgh, Pennsylvania, Court of Federal Claims No: 22-0176V
45. Alexis Dimick, Phoenix, Arizona, Court of Federal Claims No: 22-0188V
46. Jacki Della Rosa Carron, Upper Arlington, Ohio, Court of Federal Claims No: 22-0189V
47. Matthew J. Miller, Fairbury, Nebraska, Court of Federal Claims No: 22-0190V
48. Tiara Pore, New Hyde Park, New York, Court of Federal Claims No: 22-0191V
49. Cheryl A. Maxheimer, Fenton, Michigan, Court of Federal Claims No: 22-0192V
50. Kari Lynn Fisher, Port Angeles, Washington, Court of Federal Claims No: 22-0195V
51. Mira Goff on behalf of the Estate of Richard Goff, Deceased, Kenton, Ohio, Court of Federal Claims No: 22-0199V
52. Gregory Mills, Texas City, Texas, Court of Federal Claims No: 22-0203V
53. Teresa Vickers on behalf of the Estate of Wanda Sovine, Deceased, Hurricane, West Virginia, Court of Federal Claims No: 22-0204V
54. Larry Toothman, East Liverpool, Ohio, Court of Federal Claims No: 22-0207V
55. Danette Weems, St. Louis, Missouri, Court of Federal Claims No: 22-0208V
56. Amelia Goff, Eufaula, Alabama, Court of Federal Claims No: 22-0209V
57. Sabine Templeton on behalf of the Estate of Ramsay Templeton, Deceased, Fernandina Beach, Florida, Court of Federal Claims No: 22-0210V
58. Mark Cunningham, Charlotte, North Carolina, Court of Federal Claims No: 22-0211V
59. Bret Wood, Concord, North Carolina, Court of Federal Claims No: 22-0212V

60. Fahtima Isaac, Phoenix, Arizona, Court of Federal Claims No: 22–0213V
61. Shannon McDonald, Lumberton, New Jersey, Court of Federal Claims No: 22–0215V
62. Anita Enns, Katy, Texas, Court of Federal Claims No: 22–0216V
63. Joyce Glenn on behalf of the Estate of Anthony Glenn, Deceased, Fontana, California, Court of Federal Claims No: 22–0217V
64. April Keen, Greenville, South Carolina, Court of Federal Claims No: 22–0218V
65. Carey Cribbs, Ferndale, Michigan, Court of Federal Claims No: 22–0219V
66. Sara Davis Buechner, Philadelphia, Pennsylvania, Court of Federal Claims No: 22–0220V
67. Rafael Mauries, Cedar Park, Texas, Court of Federal Claims No: 22–0224V

[FR Doc. 2022–06249 Filed 3–23–22; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Tick-Borne Disease Working Group

AGENCY: Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: As required by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the Tick-Borne Disease Working Group (TBDWG) will hold a virtual meeting. The meeting will be open to the public. For this meeting, the TBDWG will be discussing and voting on recommendations for the 2022 TBDWG Report to the HHS Secretary and Congress. Most of the recommendations the TBDWG will consider are from the reports of five TBDWG subcommittees, which were created to examine critical topic areas related to tick-borne diseases. The 2022 report will address a wide range of topics related to tick-borne diseases, such as, surveillance, prevention, diagnosis, diagnostics, and treatment; identify advances made in research, as well as overlap and gaps in tick-borne disease research; and provide recommendations regarding any appropriate changes or improvements to such activities and research.

DATES: The meeting will be held online via webcast on April 27, 2022–April 28,

2022 from approximately 9:00 a.m. to 5:00 p.m. ET (times are tentative and subject to change) each day. The confirmed times and agenda items for the meeting will be posted on the TBDWG web page <https://www.hhs.gov/ash/advisory-committees/tickborne-disease/meetings/2022-04-27/index.html> when this information becomes available.

FOR FURTHER INFORMATION CONTACT:

James Berger, Designated Federal Officer for the TBDWG; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Mary E. Switzer Building, 330 C Street SW, Suite L600, Washington, DC 20024. Email: tickbornedisease@hhs.gov. Phone: 202–795–7608.

SUPPLEMENTARY INFORMATION:

Registration information can be found on the meeting website at <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/2022-04-27/index.html> when it becomes available. The public will have an opportunity to present their views to the TBDWG orally during the meeting’s public comment session or by submitting a written public comment. Comments should be pertinent to the meeting discussion. Persons who wish to provide verbal or written public comment should review instructions at <https://www.hhs.gov/ash/advisory-committees/tickborne-disease/meetings/2022-04-27/index.html> and respond by midnight April 15, 2022 ET. Verbal comments will be limited to three minutes each to accommodate as many speakers as possible during the 30 minute session. Written public comments will be accessible to the public on the TBDWG web page prior to the meeting.

Background and Authority: The Tick-Borne Disease Working Group was established on August 10, 2017, in accordance with Section 2062 of the 21st Century Cures Act, and the Federal Advisory Committee Act, 5 U.S.C. App., as amended, to provide expertise and review federal efforts related to all tick-borne diseases, to help ensure interagency coordination and minimize overlap, and to examine research priorities. The TBDWG is required to submit a report to the HHS Secretary and Congress on their findings and any recommendations for the federal response to tick-borne disease every two years.

Dated: March 14, 2022.

James J. Berger,

Designated Federal Officer, Tick-Borne Disease Working Group, Office of Infectious Disease and HIV/AIDS Policy.

[FR Doc. 2022–06226 Filed 3–23–22; 8:45 am]

BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against Hui (Herb) Bin Sun, Ph.D. (Respondent), formerly Professor of Orthopedic Surgery and Radiation Oncology, Albert Einstein College of Medicine (AECM). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), grant R01 AR050968 and National Heart, Lung, and Blood Institute (NHLBI), NIH, grant P01 HL110900. The administrative actions, including supervision for a period of twelve (12) years, were implemented beginning on March 1, 2022, and are detailed below.

FOR FURTHER INFORMATION CONTACT:

Wanda K. Jones, Dr.P.H., Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Hui (Herb) Bin Sun, Ph.D., Albert Einstein College of Medicine: Based on the report of an investigation conducted by AECM and analysis conducted by ORI in its oversight review, ORI found that Dr. Sun, formerly Professor of Orthopedic Surgery and Radiation Oncology, AECM, engaged in research misconduct in research supported by PHS funds, specifically NIAMS, NIH, grant R01 AR050968 and NHLBI, NIH, grant P01 HL110900.

ORI found that Respondent engaged in research misconduct by intentionally, knowingly, or recklessly falsifying and/or fabricating data included in sixteen (16) grant applications submitted for PHS funds:

- R01 AR065563–01, “CITED2 and Chondroprotection,” submitted to NIAMS, NIH, on 02/05/2013.